CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Iodixanol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01848899
NCT01848899Phase 4Completed
CompareCT.gov

The Assesment of Thrombotic Markers Utilizing Ionic Versus Non-Ionic Contrast During Coronary Angiography and Intervention (AToMIC) Trial

NYU Langone Health·interventional·Posted May 8, 2013·Updated Apr 6, 2016

In Brief

A Phase 4 clinical trial evaluating Iodixanol, Ioxaglate, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet function in patients undergoing coronary angiography, and if the use of bivalirudin, a direct thrombin inhibitor used during percutaneous coronary intervention (PCI), affects any contrast-related changes in thrombogenesis and platelet function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsGuerbet

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2013
Enrollment StartFeb 1, 2013
Primary CompletionNov 1, 2013
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.2 years ago

Interventions

Iodixanoldrug

contrast media used during coronary angiography

Ioxaglatedrug

contrast media used during coronary angiography

Bivalirudindrug

A direct thrombin inhibitor